MX2024003580A - Metodos de tratamiento de enfermedades inflamatorias oculares. - Google Patents
Metodos de tratamiento de enfermedades inflamatorias oculares.Info
- Publication number
- MX2024003580A MX2024003580A MX2024003580A MX2024003580A MX2024003580A MX 2024003580 A MX2024003580 A MX 2024003580A MX 2024003580 A MX2024003580 A MX 2024003580A MX 2024003580 A MX2024003580 A MX 2024003580A MX 2024003580 A MX2024003580 A MX 2024003580A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- treatment
- eye diseases
- inflammatory eye
- inflammatory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247174P | 2021-09-22 | 2021-09-22 | |
| US202163251874P | 2021-10-04 | 2021-10-04 | |
| PCT/US2022/076876 WO2023049809A1 (en) | 2021-09-22 | 2022-09-22 | Methods of treating ocular inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003580A true MX2024003580A (es) | 2024-04-05 |
Family
ID=85571480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003580A MX2024003580A (es) | 2021-09-22 | 2022-09-22 | Metodos de tratamiento de enfermedades inflamatorias oculares. |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12263160B2 (https=) |
| EP (1) | EP4405048A4 (https=) |
| JP (1) | JP2024534570A (https=) |
| AU (1) | AU2022353032A1 (https=) |
| CA (1) | CA3231766A1 (https=) |
| IL (1) | IL311534A (https=) |
| MX (1) | MX2024003580A (https=) |
| WO (1) | WO2023049809A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US12564616B2 (en) * | 2022-05-20 | 2026-03-03 | Sol Gersh | Composition for respiratory diseases |
| CN116919958A (zh) * | 2023-07-05 | 2023-10-24 | 南方医科大学口腔医院 | 罗氟司特在骨缺损修复治疗中的应用 |
| WO2025024684A1 (en) * | 2023-07-25 | 2025-01-30 | Iolyx Therapeutics, Inc. | Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| SK122199A3 (en) * | 1997-03-18 | 2000-12-11 | Basf Ag | Methods and compositions for modulating responsiveness to corticosteroids |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20040242597A1 (en) * | 2001-09-19 | 2004-12-02 | Thomas Klein | Combination |
| PT1511516E (pt) | 2002-05-28 | 2009-02-20 | Nycomed Gmbh | Preparação farmacêutica para aplicação tópica |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| AU2005267706B2 (en) | 2004-08-02 | 2011-12-08 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| US7576069B2 (en) | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| DE102004046235A1 (de) | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
| US8663694B2 (en) | 2005-03-16 | 2014-03-04 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
| DK1906916T3 (da) | 2005-05-10 | 2009-01-19 | Alcon Inc | Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser |
| BRPI0609227A2 (pt) | 2005-05-10 | 2010-03-09 | Alcon Inc | composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos |
| EP1889620A4 (en) * | 2005-06-09 | 2008-12-10 | Santen Pharmaceutical Co Ltd | EYE DROPS CONTAINING ROFLUMILAST |
| US20090092574A1 (en) | 2006-12-29 | 2009-04-09 | Scott Richard W | Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof |
| CA2712017C (en) | 2008-01-18 | 2016-08-09 | Oxagen Limited | Compounds having crth2 antagonist activity |
| RS54413B1 (sr) | 2008-08-22 | 2016-04-28 | Sanofi | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita |
| EP2506878A2 (en) | 2009-12-03 | 2012-10-10 | Lupin Limited | Process for preparing pharmaceutical ophthalmic compositions |
| US9308213B2 (en) | 2010-10-29 | 2016-04-12 | Infirst Healthcare Limited | Solid solution compositions and use in chronic inflammation |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| WO2014072937A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| WO2014130922A1 (en) | 2013-02-25 | 2014-08-28 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
| WO2015132708A1 (en) | 2014-03-07 | 2015-09-11 | Torrent Pharmaceuticals Limited | Pharmaceutical composition of roflumilast |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| TW201729810A (zh) | 2015-10-26 | 2017-09-01 | 札爾科製藥公司 | 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法 |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| MX2021003633A (es) | 2018-10-16 | 2021-05-27 | Res Triangle Inst | Dispositivo de depósito biodegradable subcutáneo. |
| EP4061332A4 (en) | 2019-11-24 | 2023-11-29 | Sol-Gel Technologies Ltd. | TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
-
2022
- 2022-09-22 WO PCT/US2022/076876 patent/WO2023049809A1/en not_active Ceased
- 2022-09-22 EP EP22873866.2A patent/EP4405048A4/en active Pending
- 2022-09-22 MX MX2024003580A patent/MX2024003580A/es unknown
- 2022-09-22 AU AU2022353032A patent/AU2022353032A1/en active Pending
- 2022-09-22 US US17/950,802 patent/US12263160B2/en active Active
- 2022-09-22 IL IL311534A patent/IL311534A/en unknown
- 2022-09-22 JP JP2024518365A patent/JP2024534570A/ja active Pending
- 2022-09-22 CA CA3231766A patent/CA3231766A1/en active Pending
-
2025
- 2025-03-06 US US19/072,354 patent/US20250195489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311534A (en) | 2024-05-01 |
| AU2022353032A1 (en) | 2024-03-28 |
| EP4405048A4 (en) | 2025-08-06 |
| CA3231766A1 (en) | 2023-03-30 |
| US20230090417A1 (en) | 2023-03-23 |
| US20250195489A1 (en) | 2025-06-19 |
| JP2024534570A (ja) | 2024-09-20 |
| US12263160B2 (en) | 2025-04-01 |
| WO2023049809A1 (en) | 2023-03-30 |
| EP4405048A1 (en) | 2024-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003580A (es) | Metodos de tratamiento de enfermedades inflamatorias oculares. | |
| EA201000441A1 (ru) | Водные офтальмологические препараты | |
| PH12020551766A1 (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| WO2020212760A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| MX391627B (es) | Aplicación cuantitativa periorbital de fármacos oftalmológicos. | |
| EA202191684A1 (ru) | Средство, содержащее урсодезоксихолевую кислоту, для лечения или профилактики пресбиопии | |
| CA3167959A1 (en) | Prodrug for the treatment of disease and injury of oxidative stress | |
| WO2022084738A3 (en) | Compounds and methods for the treatment of ocular disorders | |
| WO2016060917A3 (en) | Formulations for histatin therapeutics | |
| WO2013184650A3 (en) | Treatment of ocular inflammatory diseases using laquinimod | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye | |
| WO2017152129A3 (en) | Treatment of glaucoma and/or retinal diseases and formulations useful therefore | |
| PH12022550003A1 (en) | Process for the preparation of sterile ophthalmic aqueous fluticasone propionate form a nanocrystals suspensions | |
| Hommer et al. | Safety and Efficacy of Adding Fixed‐Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma | |
| MX2023004539A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| MX2025007776A (es) | Conjugados de farmaco para el tratamiento de trastornos oculares | |
| RU2575966C2 (ru) | Способ лечения неоваскулярной глаукомы | |
| AU2020299145A8 (en) | Compositions and methods for treating eye diseases | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| MX2023004538A (es) | Compuestos y metodos para el tratamiento de trastornos oculares. | |
| Galindo-Bocero et al. | Radiation retinopathy secondary to treatment of maxillary sinus carcinoma: a dramatic case | |
| MX2022009136A (es) | Composicion farmaceutica oftalmica y uso de la misma. |